Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

EDIT - Editas Medicine, Inc. So'nggi Yangiliklar | Finranks

Home

EDIT

E

Editas Medicine, Inc. (EDIT)

NMS – Real vaqt narxi. Valyuta: USD

2.23

-0.09 (-3.88%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.18

-0.05 (-2.14%)

Bozordan keyin: Mar 27, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board's (PTAB's) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad).

Is Editas Medicine Going to $0?

Is Editas Medicine Going to $0?

Editas Medicine has been on fire over the trailing-12-month period. However, the stock has been crushed since 2021, as it has faced plenty of setbacks.

Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.55 per share a year ago.

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates.

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in March:

Videolar

No Data

There is no data to display

Press-relizlar

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board's (PTAB's) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad).

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates.

Genflow Biosciences PLC Announces Directorate Change

Genflow Biosciences PLC Announces Directorate Change

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401's potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial human proof-of-concept data by year-end 2026 Extended cash runway into the third quarter of 2027 , enabling progression of EDIT-401 beyond initial human proof-of-concept data CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2025 and provided business updates.